Acute kidney injury due to anti-tuberculosis drugs

A five-year experience in an aging population

Chia Hao Chang, Yen Fu Chen, Vin Cent Wu, Chin Chung Shu, Chih Hsin Lee, Jann Yuan Wang, Li Na Lee, Chong Jen Yu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population. This study aimed to calculate the incidence of AKI due to anti-TB drugs and analyze the outcomes and predictors of renal recovery.Methods: From 2006 to 2010, patients on anti-TB treatment were identified and their medical records reviewed. Acute kidney injury was defined according to the criteria established by the AKI Network, while renal recovery was defined as a return of serum creatinine to baseline. Predictors of renal recovery were identified by Cox regression analysis.Results: Ninety-nine out of 1394 (7.1%) patients on anti-TB treatment had AKI. Their median age was 68 years and there was male predominance. Sixty (61%) developed AKI within two months of anti-TB treatment, including 11 (11%) with a prior history of rifampin exposure. Thirty (30%) had co-morbid chronic kidney disease or end-stage renal disease. The median time of renal recovery was 39.6 days (range, 1-180 days). Factors predicting renal recovery were the presence of fever, rash, and gastro-intestinal disturbance at the onset of AKI. Sixty-two of the 71 (87%) patients who recovered from AKI had successful re-introduction or continuation of rifampin.Conclusions: Renal function impairment is not a rare complication during anti-TB treatment in an elderly population. The presence of fever and rash may be associated with renal recovery. Rifampin can still be used in most patients who recover from AKI.

Original languageEnglish
Article number23
JournalBMC Infectious Diseases
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 13 2014

Fingerprint

Acute Kidney Injury
Tuberculosis
Kidney
Pharmaceutical Preparations
Population
Rifampin
Exanthema
Fever
Therapeutics
Chronic Renal Insufficiency
Chronic Kidney Failure
Medical Records
Creatinine
Regression Analysis
Incidence
Serum

Keywords

  • Acute kidney injury
  • Anti-tuberculosis drug
  • Fever
  • Rash
  • Rifampin

ASJC Scopus subject areas

  • Infectious Diseases
  • Medicine(all)

Cite this

Acute kidney injury due to anti-tuberculosis drugs : A five-year experience in an aging population. / Chang, Chia Hao; Chen, Yen Fu; Wu, Vin Cent; Shu, Chin Chung; Lee, Chih Hsin; Wang, Jann Yuan; Lee, Li Na; Yu, Chong Jen.

In: BMC Infectious Diseases, Vol. 14, No. 1, 23, 13.01.2014.

Research output: Contribution to journalArticle

Chang, Chia Hao ; Chen, Yen Fu ; Wu, Vin Cent ; Shu, Chin Chung ; Lee, Chih Hsin ; Wang, Jann Yuan ; Lee, Li Na ; Yu, Chong Jen. / Acute kidney injury due to anti-tuberculosis drugs : A five-year experience in an aging population. In: BMC Infectious Diseases. 2014 ; Vol. 14, No. 1.
@article{29f67a871a33443c9b1d5fb95aebff6f,
title = "Acute kidney injury due to anti-tuberculosis drugs: A five-year experience in an aging population",
abstract = "Background: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population. This study aimed to calculate the incidence of AKI due to anti-TB drugs and analyze the outcomes and predictors of renal recovery.Methods: From 2006 to 2010, patients on anti-TB treatment were identified and their medical records reviewed. Acute kidney injury was defined according to the criteria established by the AKI Network, while renal recovery was defined as a return of serum creatinine to baseline. Predictors of renal recovery were identified by Cox regression analysis.Results: Ninety-nine out of 1394 (7.1{\%}) patients on anti-TB treatment had AKI. Their median age was 68 years and there was male predominance. Sixty (61{\%}) developed AKI within two months of anti-TB treatment, including 11 (11{\%}) with a prior history of rifampin exposure. Thirty (30{\%}) had co-morbid chronic kidney disease or end-stage renal disease. The median time of renal recovery was 39.6 days (range, 1-180 days). Factors predicting renal recovery were the presence of fever, rash, and gastro-intestinal disturbance at the onset of AKI. Sixty-two of the 71 (87{\%}) patients who recovered from AKI had successful re-introduction or continuation of rifampin.Conclusions: Renal function impairment is not a rare complication during anti-TB treatment in an elderly population. The presence of fever and rash may be associated with renal recovery. Rifampin can still be used in most patients who recover from AKI.",
keywords = "Acute kidney injury, Anti-tuberculosis drug, Fever, Rash, Rifampin",
author = "Chang, {Chia Hao} and Chen, {Yen Fu} and Wu, {Vin Cent} and Shu, {Chin Chung} and Lee, {Chih Hsin} and Wang, {Jann Yuan} and Lee, {Li Na} and Yu, {Chong Jen}",
year = "2014",
month = "1",
day = "13",
doi = "10.1186/1471-2334-14-23",
language = "English",
volume = "14",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Acute kidney injury due to anti-tuberculosis drugs

T2 - A five-year experience in an aging population

AU - Chang, Chia Hao

AU - Chen, Yen Fu

AU - Wu, Vin Cent

AU - Shu, Chin Chung

AU - Lee, Chih Hsin

AU - Wang, Jann Yuan

AU - Lee, Li Na

AU - Yu, Chong Jen

PY - 2014/1/13

Y1 - 2014/1/13

N2 - Background: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population. This study aimed to calculate the incidence of AKI due to anti-TB drugs and analyze the outcomes and predictors of renal recovery.Methods: From 2006 to 2010, patients on anti-TB treatment were identified and their medical records reviewed. Acute kidney injury was defined according to the criteria established by the AKI Network, while renal recovery was defined as a return of serum creatinine to baseline. Predictors of renal recovery were identified by Cox regression analysis.Results: Ninety-nine out of 1394 (7.1%) patients on anti-TB treatment had AKI. Their median age was 68 years and there was male predominance. Sixty (61%) developed AKI within two months of anti-TB treatment, including 11 (11%) with a prior history of rifampin exposure. Thirty (30%) had co-morbid chronic kidney disease or end-stage renal disease. The median time of renal recovery was 39.6 days (range, 1-180 days). Factors predicting renal recovery were the presence of fever, rash, and gastro-intestinal disturbance at the onset of AKI. Sixty-two of the 71 (87%) patients who recovered from AKI had successful re-introduction or continuation of rifampin.Conclusions: Renal function impairment is not a rare complication during anti-TB treatment in an elderly population. The presence of fever and rash may be associated with renal recovery. Rifampin can still be used in most patients who recover from AKI.

AB - Background: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population. This study aimed to calculate the incidence of AKI due to anti-TB drugs and analyze the outcomes and predictors of renal recovery.Methods: From 2006 to 2010, patients on anti-TB treatment were identified and their medical records reviewed. Acute kidney injury was defined according to the criteria established by the AKI Network, while renal recovery was defined as a return of serum creatinine to baseline. Predictors of renal recovery were identified by Cox regression analysis.Results: Ninety-nine out of 1394 (7.1%) patients on anti-TB treatment had AKI. Their median age was 68 years and there was male predominance. Sixty (61%) developed AKI within two months of anti-TB treatment, including 11 (11%) with a prior history of rifampin exposure. Thirty (30%) had co-morbid chronic kidney disease or end-stage renal disease. The median time of renal recovery was 39.6 days (range, 1-180 days). Factors predicting renal recovery were the presence of fever, rash, and gastro-intestinal disturbance at the onset of AKI. Sixty-two of the 71 (87%) patients who recovered from AKI had successful re-introduction or continuation of rifampin.Conclusions: Renal function impairment is not a rare complication during anti-TB treatment in an elderly population. The presence of fever and rash may be associated with renal recovery. Rifampin can still be used in most patients who recover from AKI.

KW - Acute kidney injury

KW - Anti-tuberculosis drug

KW - Fever

KW - Rash

KW - Rifampin

UR - http://www.scopus.com/inward/record.url?scp=84892412208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892412208&partnerID=8YFLogxK

U2 - 10.1186/1471-2334-14-23

DO - 10.1186/1471-2334-14-23

M3 - Article

VL - 14

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 23

ER -